1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5-oxadiazole derivatives.
1. A method of inhibiting or ameliorating a cancer selected from renal cancer, lung cancer, and head and neck cancer in a patient, comprising administering to said patient a therapeutically effective amount of a compound, which is 4-({2-[(amino sulfonyl)amino]ethyl}amino)-N-(3-bromo-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide, or a pharmaceutically acceptable salt thereof, in combination with an antibody therapeutic.
2. The method of claim 1 , wherein the cancer is renal cancer.
3. The method of claim 2 , wherein the antibody therapeutic is an anti-PD-1 antibody.
4. The method of claim 2 , wherein the antibody therapeutic is an anti-CTLA-4 antibody.
5. The method of claim 1 , wherein the cancer is lung cancer.
6. The method of claim 5 , wherein the antibody therapeutic is an anti-PD-1 antibody.
7. The method of claim 5 , wherein the antibody therapeutic is an anti-CTLA-4 antibody.
8. The method of claim 1 , wherein the cancer is head and neck cancer.
9. The method of claim 8 , wherein the antibody therapeutic is an anti-PD-1 antibody.
10. The method of claim 8 , wherein the antibody therapeutic is an anti-CTLA-4 antibody.
11. A method of inhibiting or ameliorating a cancer selected from renal cancer, lung cancer, and head and neck cancer in a patient, comprising administering to said patient a therapeutically effective amount of a compound, which is 4-({2-[(amino sulfonyl)amino]ethyl}amino)-N-(3-bromo-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide in combination with an antibody therapeutic.
12. The method of claim 11 , wherein the cancer is renal cancer.
13. The method of claim 12 , wherein the antibody therapeutic is an anti-PD-1 antibody.
14. The method of claim 12 , wherein the antibody therapeutic is an anti-CTLA-4 antibody.
15. The method of claim 11 , wherein the cancer is lung cancer.
16. The method of claim 15 , wherein the antibody therapeutic is an anti-PD-1 antibody.
17. The method of claim 15 , wherein the antibody therapeutic is an anti-CTLA-4 antibody.
18. The method of claim 11 , wherein the cancer is head and neck cancer.
19. The method of claim 18 , wherein the antibody therapeutic is an anti-PD-1 antibody.
20. The method of claim 18 , wherein the antibody therapeutic is an anti-CTLA-4 antibody.